2024年美国风湿病学会(ACR)狼疮性肾炎筛查、治疗和管理指南
该指南由核心团队以PICO格式提出狼疮性肾炎筛查、治疗和管理临床问题,系统文献综述采用GRADE方法评估证据质量并形成推荐,投票面板对每条推荐的方向和强度达成≥70%共识。共给出28条分级推荐(7条强推荐、21条条件推荐)和13条未分级、基于共识的良好实践声明,核心原则是狼疮性肾炎治疗为持续不间断过程而非离散的诱导/初始与维持/后续治疗。
要点
- 指南提出28条分级推荐(7条强推荐、21条条件推荐)和13条未分级共识良好实践声明。
- 核心原则:狼疮性肾炎治疗是持续不间断的,而非离散的诱导/初始与维持/后续治疗。
- 达到完全肾脏缓解者,治疗应包括脉冲糖皮质激素后口服糖皮质激素逐渐减量,并加用两种其他免疫抑制剂,持续3-5年。
核心结论
- 该指南为临床医生管理狼疮性肾炎的筛查和治疗决策提供方向。
- 这些推荐不应用于限制或拒绝患者获得治疗,因为治疗决策可能因每位患者独特的临床情况和偏好而异。
研究设计与样本
- 核心团队使用PICO格式(人群、干预、对照、结局)提出狼疮性肾炎筛查、治疗和管理的临床问题。
- 针对每个PICO问题完成系统文献综述,采用GRADE方法评估证据质量并形成推荐。
- 投票面板对每条推荐的方向(支持或反对)和强度(强或条件)达成≥70%共识。
主要发现
- 共给出28条分级推荐(7条强推荐、21条条件推荐)和13条未分级、基于共识的良好实践声明,用于狼疮性肾炎的筛查和管理。
- 推荐聚焦于统一原则:狼疮性肾炎治疗是持续不间断的,而非由离散的诱导/初始治疗和维持/后续治疗组成。
- 治疗应包括脉冲糖皮质激素后口服糖皮质激素逐渐减量,并加用两种其他免疫抑制剂,对达到完全肾脏缓解者持续3-5年。
关键数值与推荐
- 共28条分级推荐:7条强推荐、21条条件推荐;另有13条未分级、基于共识的良好实践声明。
- 投票面板对每条推荐的方向和强度达成≥70%共识。
- 达到完全肾脏缓解者:脉冲糖皮质激素后口服糖皮质激素逐渐减量,加用两种其他免疫抑制剂,持续3-5年。
临床怎么用
- 临床医生可依据该指南进行狼疮性肾炎的筛查和治疗决策。
- 这些推荐不应用于限制或拒绝患者获得治疗,治疗决策可能因患者独特临床情况和偏好而异。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The objective is to provide evidence-based and expert guidance for the screening, treatment, and management of lupus nephritis. METHODS: The Core Team developed clinical questions for screening, treatment, and management of lupus nephritis using the PICO format (population, intervention, comparator, and outcome). Systematic literature reviews were completed for each PICO question, and the Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology was used to assess the quality of evidence and to formulate recommendations. The Voting Panel achieved a consensus ≥70% on the direction (for or against) and strength (strong or conditional) of each recommendation. RESULTS: We present 28 graded recommendations (7 strong, 21 conditional) and 13 ungraded, consensus-based good practice statements for the screening and management of lupus nephritis. Our recommendations focus on the unifying principle that lupus nephritis therapy is continuous and ongoing, rather than consisting of discrete induction/initial and maintenance/subsequent therapies. Therapy should include pulse glucocorticoids followed by oral glucocorticoid taper and two additional immunosuppressive agents for 3-5 years for those achieving complete renal response. CONCLUSION: This guideline provides direction for clinicians regarding screening and treatment decisions for management of lupus nephritis. These recommendations should not be used to limit or deny access to therapies, as treatment decisions may vary due to the unique clinical situation and personal preferences of each individual patient.
引用
- Sammaritano LR, Askanase A, Bermas BL, et al. 2024 American College of Rheumatology (ACR) Guideline for the Screening, Treatment, and Management of Lupus Nephritis. Arthritis Rheumatol. 2025. PMID: 40331662. doi:10.1002/art.43212
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。